Titan Biotech Ltd Fair Value
TITANBIO · Commodities · Current price ₹428.7
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹44 | 12% ROE fading to 13% over ~3 yrs, on ₹44 book |
| Relative P/E | ₹949 | EPS × 31.3 peer-median P/E |
| Graham floor | ₹173 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is Titan Biotech Ltd undervalued?
DocStoX estimates the fair value of Titan Biotech Ltd at ₹306 per share, versus the current market price of ₹429. That puts the stock about -28.6% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹44), Relative P/E (₹949), Graham floor (₹173). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹44 (bear) to ₹306 (base) to ₹949 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on Titan Biotech Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.